lenalidomide + dexamethasone + cyclophosphamide

This combination therapy regimen, often abbreviated as RdC or CRd, consists of the immunomodulatory drug lenalidomide, the alkylating agent cyclophosphamide, and the corticosteroid dexamethasone. It was evaluated in a Phase I/II clinical trial (NCT00981708) led by the University of Athens School of Medicine for the treatment of primary systemic light-chain (AL) amyloidosis. The regimen is designed to target the underlying plasma cell clone responsible for producing toxic amyloidogenic light chains. Lenalidomide acts by modulating the immune system and inducing the degradation of specific transcription factors via the cereblon E3 ubiquitin ligase complex; cyclophosphamide acts as a cytotoxic alkylating agent that cross-links DNA to inhibit cell division; and dexamethasone provides anti-inflammatory and lympholytic effects while synergistically enhancing the activity of the other agents.

Other names

RdC regimenCRd regimenlenalidomide, cyclophosphamide, and dexamethasone